Drug intelligence / Profile preview

faecalibacterium prausnitzii + desulfovibrio piger

Development stage: Unknown
Lead developer: MetaboGen
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

SiP-001 is a next-generation live biotherapeutic product (LBP) consisting of a symbiotic consortium of two anaerobic gut bacterial strains: *Faecalibacterium prausnitzii* (DSM 32186) and *Desulfovibrio piger* (DSM 32187). The formulation leverages a unique metabolic cross-feeding relationship where *D. piger* consumes hydrogen produced by *F. prausnitzii*. This removal of hydrogen relieves metabolic inhibition, promoting the growth and biomass of *F. prausnitzii* and significantly enhancing the production of butyrate, a short-chain fatty acid (SCFA) essential for maintaining gut barrier integrity and regulating metabolic homeostasis. Developed by Metabogen (a subsidiary of BioGaia), SiP-001 has been investigated in Phase 1 clinical trials (NCT03728868) for the treatment of metabolic diseases, including type 2 diabetes and metabolic syndrome, as well as inflammatory bowel conditions.

Other names: Faecalibacterium prausnitzii DSM 32186 + Desulfovibrio piger DSM 32187Symbiotic Product 1

Beyond the preview

Go deeper on faecalibacterium prausnitzii + desulfovibrio piger.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on faecalibacterium prausnitzii + desulfovibrio piger.

Explore the full profile